Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 10/20 | 0.48 |
| ▸ | IDH1 | O75874 | 5/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20445801 | 1.00 | RPS6KB1 (0.48) | RPS6KB1IDH1HDAC1HDAC6HDAC3 | |
| SCHEMBL20445793 | 0.85 | RPS6KB1 (0.52) | RPS6KB1IDH1 | |
| SCHEMBL20445792 | 0.85 | RPS6KB1 (0.52) | RPS6KB1IDH1 | |
| SCHEMBL18171867 | 0.83 | LPL (0.39) | RPS6KB1IDH1 | |
| SCHEMBL18171882 | 0.80 | NUDT1 (0.40) | HDAC1HDAC6HDAC4 | |
| SCHEMBL29545777 | 0.80 | EGFR (0.39) | — | |
| SCHEMBL1368949 | 0.80 | EGFR (0.39) | — | |
| SCHEMBL25454628 | 0.79 | DGAT1 (0.36) | — | |
| SCHEMBL20445886 | 0.77 | RPS6KB1 (0.49) | RPS6KB1 | |
| SCHEMBL20445851 | 0.76 | RPS6KB1 (0.55) | RPS6KB1HDAC1HDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3868751-B1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| EP-3356348-B1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| CN-108473472-B | 2-aminoquinazoline derivatives as P70S6kinase inhibitors | 圣提内尔肿瘤学有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-10730882-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2020-08-04 | — | — | US | disclosed |
| US-20190292195-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2019-09-26 | — | — | US | disclosed |
| US-10344033-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20180370975-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| EP-3356348-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292195-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | RPS6KA1, MTOR, RPTOR | RPS6KB1 6/4885IDH1 1656/4885HDAC1 538/4885 |
| US-20180370975-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | RPS6KA1, MTOR, RPTOR | RPS6KB1 6/4885IDH1 1656/4885HDAC1 538/4885 |
| US-10344033-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | RPS6KA1, MTOR, RPTOR | RPS6KB1 6/4885IDH1 1656/4885HDAC1 538/4885 |
| US-10730882-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | RPS6KA1, MTOR, RPTOR | RPS6KB1 6/4885IDH1 1656/4885HDAC1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.